A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
Public ClinicalTrials.gov record NCT06163326. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSE-UP TITRATION, MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY, EFFICACY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV). Ritlecitinib is studied in patients with non-segmental vitiligo. Vitiligo is a chronic acquired depigmentation disorder characterized by well-defined pale white patches of skin. Non-segmental vitiligo is an autoimmune disorder and is the focus of this study. The study will show: * if the repigmentation (the recovery of pigmentation) achieved in study B7981040 (also called the "parent study") will stay the same or will further increase if you keep receiving the same study medicine (ritlecitinib 50 milligrams or placebo) * Or if more repigmentation can be achieved if you start receiving ritlecitinib 100 milligrams in this study * Or how long the repigmentation achieved during the parent study lasts if you start receiving placebo in this study. This study is seeking for participants who: * have non-segmental vitiligo (either active or stable) and * received ritlecitinib or placebo for 52 weeks in the parent study. A placebo looks exactly like the study capsule but does not contain any medicine in it. All participants in this study will receive the study medicine or placebo. The study medicine (ritlecitinib 50 milligrams or 100 milligrams) or placebo are capsules that are taken by mouth at home every day. On study visit days, you must take the medication at the study site, and not at home. Participants may receive the study medicine or placebo for up to 52 weeks. The study will look at the experiences of people receiving the study medicine. This will help see if ritlecitinib is better for treating vitiligo. Participants will be involved in this study for a maximum of 60 weeks. During this time, they will have 9 study visits during the study. Ritlecitinib 50 mg is an approved drug for the treatment of severe Alopecia Areata (a disease with similar abnormal changes in the body functions like vitiligo) in the US, EU and Japan. China, Great Britain and other market applications are pending.
Study identification
- NCT ID
- NCT06163326
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 394 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 19, 2024 (Actual)
- Primary completion
- Mar 31, 2027 (Estimated)
- Completion
- Mar 31, 2027 (Estimated)
- Last update posted
- Sep 28, 2026
2024 – 2027
United States locations
- U.S. sites
- 22
- U.S. states
- 12
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California Dermatology & Clinical Research Institute | Encinitas | California | 92024 | — |
| Marvel Clinical Research | Huntington Beach | California | 92647 | — |
| Wallace Medical Group, Inc | Los Angeles | California | 90056 | — |
| Encore Medical Research of Boynton Beach | Boynton Beach | Florida | 33436 | — |
| Skin Care Research | Hollywood | Florida | 33021 | — |
| ForCare Clinical Research | Tampa | Florida | 33613 | — |
| Dawes Fretzin Clinical Research Group, LLC | Indianapolis | Indiana | 46250 | — |
| DelRicht Research | Baton Rouge | Louisiana | 70809 | — |
| Lawrence J. Green, MD LLC | Rockville | Maryland | 20850 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| University of New Mexico Health Sciences Center | Albuquerque | New Mexico | 87102 | — |
| SUNY Downstate Health Sciences University | Brooklyn | New York | 11203 | — |
| University of North Carolina Medical Center | Chapel Hill | North Carolina | 27516 | — |
| Clinical & Translational Research Center (CTRC) | Chapel Hill | North Carolina | 27599 | — |
| Accellacare - Wilmington | Wilmington | North Carolina | 28411 | — |
| Wilmington Health, PLLC | Wilmington | North Carolina | 28411 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| Remington-Davis, Inc | Columbus | Ohio | 43215 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| Modern Research Associates, PLLC | Dallas | Texas | 75231 | — |
| Alpesh D. Desai, DO PLLC | Houston | Texas | 77008 | — |
| Austin Institute for Clinical Research | Houston | Texas | 77056 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 51 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06163326, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 28, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06163326 live on ClinicalTrials.gov.